Long-term Outcomes of New Systemic Agents in Atopic Dermatitis: Drug Survival Analyses and Treatment Patterns in Daily Practice
Acta Dermato-Venereologica · 09.03.2025 · 105 · adv41504
DOI: 10.2340/actadv.v105.41504 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Acta Dermato-Venereologica, online erschienen am 09.03.2025. Verfasst von Anne R Schlosser und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands. a.schlosser@erasmusmc.nl. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Janus Kinase Inhibitors, Practice Patterns, Physicians', Biological Products. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
In recent years, several new systemic agents (biologics and Janus kinase inhibitors [JAKi]) have been registered for the treatment of moderate-to-severe atopic dermatitis (AD). However, comparisons of real-world drug survival data and insights into treatment patterns of these advanced systemics are limited. Data from a prospective observational single-centre registry were collected from 549 adult AD patients (759 treatment courses) receiving biologics (dupilumab, tralokinumab) or JAKi (abrocitinib, baricitinib, upadacitinib) and analysed using Kaplan–Meier survival curves. Cox regression analyses were used to evaluate predictors of survival. Frequencies and percentages summarized data on the initial and subsequent treatments received, with a Sankey diagram illustrating the switching patterns. The 18-month overall drug survival rates for dupilumab, abrocitinib, upadacitinib, tralokinumab, and baricitinib were 70.0%, 51.5%, 48.4%, 39.4%, and 20.4%, respectively. No significant predictors for drug survival were identified. Dupilumab was the predominant initial treatment (87.2%) and upadacitinib the most frequently used second and third treatment. In the total cohort, 57.9% of patients remained on their initial treatment and 26.8% switched to other treatments. In conclusion, dupilumab showed superior survival rates while baricitinib had the lowest survival rate. Frequent switching highlights the need for biomarkers that predict response to advanced systemic treatments to improve attrition rates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands. a.schlosser@erasmusmc.nl.
- Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
ORCID-Profile: Anne R Schlosser, Renske Schappin, Tamar E C Nijsten, Dirkjan Hijnen
Zitieren
APA
Schlosser, A. R., Nijman, L., Schappin, R., Nijsten, T. E. C., & Hijnen, D. (2025). Long-term Outcomes of New Systemic Agents in Atopic Dermatitis: Drug Survival Analyses and Treatment Patterns in Daily Practice. Acta Dermato-Venereologica, 105, adv41504. https://doi.org/10.2340/actadv.v105.41504
Vancouver
Schlosser AR, Nijman L, Schappin R, Nijsten TEC, Hijnen D. Long-term Outcomes of New Systemic Agents in Atopic Dermatitis: Drug Survival Analyses and Treatment Patterns in Daily Practice. Acta Dermato-Venereologica. 2025;105:adv41504. doi:10.2340/actadv.v105.41504
BibTeX
@article{Schlosser2025,
author = {Schlosser, Anne R and Nijman, Lars and Schappin, Renske and Nijsten, Tamar E C and Hijnen, Dirkjan},
title = {Long-term Outcomes of New Systemic Agents in Atopic Dermatitis: Drug Survival Analyses and Treatment Patterns in Daily Practice},
journal = {Acta Dermato-Venereologica},
year = {2025},
volume = {105},
pages = {adv41504},
doi = {10.2340/actadv.v105.41504}
}
EUVIMED